Bloomberg -- AstraZeneca Plc’s experimental thyroid cancer treatment may cause “substantial toxicity,” according to U.S. regulators weighing whether the product should be approved for sale.
Bloomberg -- AstraZeneca Plc’s experimental thyroid cancer treatment may cause “substantial toxicity,” according to U.S. regulators weighing whether the product should be approved for sale.
